 During the course of the trial, Olivieri became concerned about evidence that pointed to the drug being inefficacious for some patients.Olivieri informed both the research ethics board that was monitoring the study and Apotex, the drug maker.The research ethics board instructed Olivieri to inform participants about her concerns.